Page 11«..10111213..2030..»

Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

By Dr. Matthew Watson

Regulated Information - Denominator

Read the original here:
Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas

To Read More: Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas
categoriaGlobal News Feed commentoComments Off on Information on the Total Number of Voting Rights (Denominator) following Conversion Notices from Atlas | dataJanuary 22nd, 2024
Read All

KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

ARLINGTON, Mass., Jan. 19, 2024 (GLOBE NEWSWIRE) -- KALA BIO, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to a new employee as an inducement award outside the Company’s Amended and Restated 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

Link:
KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on KALA BIO Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataJanuary 22nd, 2024
Read All

TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

By Dr. Matthew Watson

MALVERN, Pa., Jan. 19, 2024 (GLOBE NEWSWIRE) -- TELA Bio, Inc. ("TELA Bio") (NASDAQ: TELA), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's own anatomy, today announced that the Compensation Committee of the Board of Directors of TELA Bio approved inducement grants of restricted stock units covering 5,500 shares of its common stock to nine newly-hired employees, with a grant date of January 18, 2024 (the "Grant Date"). The restricted stock units were granted pursuant to the Nasdaq Rule 5635(c)(4) inducement grant exception as a component of each individual's employment compensation and were granted as an inducement material to his or her acceptance of employment with TELA Bio.

Go here to see the original:
TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

To Read More: TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
categoriaGlobal News Feed commentoComments Off on TELA Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | dataJanuary 22nd, 2024
Read All

Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

By Dr. Matthew Watson

Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement Apollomics has an initial 180-day period through July 15, 2024 to regain compliance with Minimum Bid Price Requirement

Read the rest here:
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

To Read More: Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
categoriaGlobal News Feed commentoComments Off on Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency | dataJanuary 22nd, 2024
Read All

Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

By Dr. Matthew Watson

Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules

Read more:
Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market

To Read More: Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market
categoriaGlobal News Feed commentoComments Off on Sandoz announces agreement to acquire CIMERLI® business from Coherus, strengthening position in US market | dataJanuary 22nd, 2024
Read All

Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

By Dr. Matthew Watson

– Transaction aligns to Coherus’ strategic focus on oncology –– Conference call Monday, January 22, 2024, at 8:30 a.m. Eastern Time –

See the original post here:
Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal

To Read More: Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal
categoriaGlobal News Feed commentoComments Off on Coherus Announces Agreement to Divest Ophthalmology Franchise to Sandoz in $170 Million Upfront All Cash Deal | dataJanuary 22nd, 2024
Read All

Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic … – Nature.com

By daniellenierenberg

Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ...  Nature.com

View original post here:
Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic ... - Nature.com

To Read More: Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic … – Nature.com
categoriaBone Marrow Stem Cells commentoComments Off on Effects of fine particulate matter on bone marrow-conserved hematopoietic and mesenchymal stem cells: a systematic … – Nature.com | dataJanuary 14th, 2024
Read All

Donating Bone Marrow and Stem Cells: The Process and What To Expect – On Cancer – Memorial Sloan Kettering

By daniellenierenberg

Donating Bone Marrow and Stem Cells: The Process and What To Expect  On Cancer - Memorial Sloan Kettering

Follow this link:
Donating Bone Marrow and Stem Cells: The Process and What To Expect - On Cancer - Memorial Sloan Kettering

To Read More: Donating Bone Marrow and Stem Cells: The Process and What To Expect – On Cancer – Memorial Sloan Kettering
categoriaBone Marrow Stem Cells commentoComments Off on Donating Bone Marrow and Stem Cells: The Process and What To Expect – On Cancer – Memorial Sloan Kettering | dataJanuary 14th, 2024
Read All

No, Rep. Steve Scalise Didn’t Vote Against Stem Cell Research From Which He Is Now Benefiting – Yahoo News

By daniellenierenberg

No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting  Yahoo News

Read more here:
No, Rep. Steve Scalise Didn't Vote Against Stem Cell Research From Which He Is Now Benefiting - Yahoo News

To Read More: No, Rep. Steve Scalise Didn’t Vote Against Stem Cell Research From Which He Is Now Benefiting – Yahoo News
categoriaBone Marrow Stem Cells commentoComments Off on No, Rep. Steve Scalise Didn’t Vote Against Stem Cell Research From Which He Is Now Benefiting – Yahoo News | dataJanuary 14th, 2024
Read All

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates … – PR Newswire

By daniellenierenberg

Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates ...  PR Newswire

Read the original here:
Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates ... - PR Newswire

To Read More: Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates … – PR Newswire
categoriaBone Marrow Stem Cells commentoComments Off on Hematopoietic Stem Cell Transplantation Market to Grow Rapidly During the Study Period (2019-2032), Evaluates … – PR Newswire | dataJanuary 14th, 2024
Read All

The Key to Creating Blood Stem Cells May Lie in Your Own Blood – ScienceAlert

By daniellenierenberg

The Key to Creating Blood Stem Cells May Lie in Your Own Blood  ScienceAlert

Originally posted here:
The Key to Creating Blood Stem Cells May Lie in Your Own Blood - ScienceAlert

To Read More: The Key to Creating Blood Stem Cells May Lie in Your Own Blood – ScienceAlert
categoriaBone Marrow Stem Cells commentoComments Off on The Key to Creating Blood Stem Cells May Lie in Your Own Blood – ScienceAlert | dataJanuary 14th, 2024
Read All

Life-saving donation from Philly athlete saves life: ‘Feeling so strong, I owe that all to him’ – AOL

By daniellenierenberg

Life-saving donation from Philly athlete saves life: 'Feeling so strong, I owe that all to him'  AOL

Read more here:
Life-saving donation from Philly athlete saves life: 'Feeling so strong, I owe that all to him' - AOL

To Read More: Life-saving donation from Philly athlete saves life: ‘Feeling so strong, I owe that all to him’ – AOL
categoriaBone Marrow Stem Cells commentoComments Off on Life-saving donation from Philly athlete saves life: ‘Feeling so strong, I owe that all to him’ – AOL | dataJanuary 14th, 2024
Read All

Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL – OncLive

By daniellenierenberg

Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL  OncLive

The rest is here:
Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL - OncLive

To Read More: Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL – OncLive
categoriaBone Marrow Stem Cells commentoComments Off on Dr Phillips on the Rationale for the GLOBRYTE Trial in Relapsed/Refractory MCL – OncLive | dataJanuary 14th, 2024
Read All

COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures – Medriva

By daniellenierenberg

COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures  Medriva

Go here to read the rest:
COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures - Medriva

To Read More: COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures – Medriva
categoriaBone Marrow Stem Cells commentoComments Off on COVID-19 and HSCT Recipients: Risk Factors and Prevention Measures – Medriva | dataJanuary 14th, 2024
Read All

Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31…

By Dr. Matthew Watson

ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE 11 JANUARY 2024 at 14.15 EET

Continue reading here:
Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31...

To Read More: Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31…
categoriaGlobal News Feed commentoComments Off on Insurance portfolio of Orion Pension Fund’s B fund transferred to an external pension insurance company – the transfer has approximately EUR 31… | dataJanuary 14th, 2024
Read All

QIAGEN N.V. to release results for Q4 2023 and hold webcast

By Dr. Matthew Watson

Venlo, The Netherlands, Jan. 11, 2024 (GLOBE NEWSWIRE) -- QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the fourth quarter and full year 2023.

Read the rest here:
QIAGEN N.V. to release results for Q4 2023 and hold webcast

To Read More: QIAGEN N.V. to release results for Q4 2023 and hold webcast
categoriaGlobal News Feed commentoComments Off on QIAGEN N.V. to release results for Q4 2023 and hold webcast | dataJanuary 14th, 2024
Read All

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

By Dr. Matthew Watson

BOSTON, Jan. 11, 2024 (GLOBE NEWSWIRE) -- TransCode Therapeutics, Inc. (NASDAQ: RNAZ) (“TransCode” or the “Company”), the RNA Oncology Company™ committed to more effectively treating cancer using RNA therapeutics, today announced that its Board of Directors has approved a 1-for-40 reverse stock split, to be effective at 12:01 a.m. Eastern Standard Time Tuesday, January 16, 2024. TransCode common stock is expected to begin trading on a split-adjusted basis on the Nasdaq Capital Market on Tuesday, January 16, 2024, under the current trading symbol, “RNAZ.” The reverse stock split was approved by TransCode’s stockholders on January 8, 2024, and is intended to increase the per share trading price of the Company's common stock to enable the Company to satisfy the minimum bid price requirement for continued listing on the Nasdaq Capital Market.

See the article here:
TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

To Read More: TransCode Therapeutics Announces 1-for-40 Reverse Stock Split
categoriaGlobal News Feed commentoComments Off on TransCode Therapeutics Announces 1-for-40 Reverse Stock Split | dataJanuary 14th, 2024
Read All

Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries

By Dr. Matthew Watson

DALLAS, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Spectral AI, Inc. (NASD:MDAI) (“Spectral AI” or the “Company”), an artificial intelligence (AI) company focused on medical diagnostics for faster and more accurate treatment decisions in clinical wound care, announces the enrollment of the first patient in the pivotal study to validate DeepView AI® using its proprietary imaging technology for burn size and healing assessment. This pivotal study is expected to be the final clinical trial before seeking FDA marketing authorization for the burn indication in 2025 and will be conducted in burn centers and emergency departments across the US, enrolling both adults and pediatric patients.

See the article here:
Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries

To Read More: Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries
categoriaGlobal News Feed commentoComments Off on Spectral AI Begins Enrollment in Pivotal Study to Validate DeepView AI® for Burn Injuries | dataJanuary 14th, 2024
Read All

Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

By Dr. Matthew Watson

MIAMI, Jan. 11, 2024 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Alexandra MacLean, M.D., Chief Executive Officer, will present a corporate update at the Sidoti January Micro-Cap Investor Conference on Thursday, January 18, 2024 at 10:00 a.m. EST.

Follow this link:
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

To Read More: Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference
categoriaGlobal News Feed commentoComments Off on Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference | dataJanuary 14th, 2024
Read All

Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

By Dr. Matthew Watson

WALTHAM, Mass., Jan. 11, 2024 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat at the B. Riley Securities 4th Annual Oncology Conference, taking place on Thursday, January 18, 2024, at 4:00 p.m. EST.

See the original post:
Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference

To Read More: Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference
categoriaGlobal News Feed commentoComments Off on Checkpoint Therapeutics to Participate in the B. Riley Securities 4th Annual Oncology Conference | dataJanuary 14th, 2024
Read All

Page 11«..10111213..2030..»


Copyright :: 2024